Skin

Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction

Retrieved on: 
Wednesday, March 27, 2024
EPS, Sale, Acquisition, Skin, Security (finance)

PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the successful closing of the previously announced sale of its wholly owned subsidiary, Axolotl Biologix (“AxoBio”) to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and cancellation of $8 million in notes payable.

Key Points: 
  • PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the successful closing of the previously announced sale of its wholly owned subsidiary, Axolotl Biologix (“AxoBio”) to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and cancellation of $8 million in notes payable.
  • Following the sale of AxoBio, Carmell’s financial position is expected to improve as follows:
    $4 million drop in annualized cash burn (net of revenue) based on AxoBio’s actual January 2024 financials.
  • $15.6 million reduction in debt: $7.6 million of AxoBio subsidiary level debt plus $8 million note payable related to the AxoBio acquisition.
  • 29% reduction in EPS dilution due to the cancellation of 8.09 million CTCX common shares on a fully diluted basis.

New York Film Academy Partners with Anica Academy to Give Master Class in Producing

Retrieved on: 
Wednesday, March 27, 2024
Online, Innovation, BAFTA, Q&A, International Emmy Awards, News, TLC, NYFA, Anica, Faculty, Student, Skin, Catalog, Lecture, Marketing, Atom Egoyan, Television, European Film Awards, Film industry

New York, NY, March 27, 2024 (GLOBE NEWSWIRE) -- In the first week of March 2024, the New York Film Academy (NYFA) Chair of the Producing Department of its New York City campus , Neal Weisman, in collaboration with Anica Academy , conducted a master class in producing.

Key Points: 
  • New York, NY, March 27, 2024 (GLOBE NEWSWIRE) -- In the first week of March 2024, the New York Film Academy (NYFA) Chair of the Producing Department of its New York City campus , Neal Weisman, in collaboration with Anica Academy , conducted a master class in producing.
  • We were very happy to host the master class ‘The Role of the Producer between the United States and Italy’ as a second appointment in 2024.
  • “This Master Class was particularly exciting because it explained the difference between the Italian and American film markets.
  • We look forward to continuing the conversation and further collaborations,” says Neal Weisman, Chair of the Producing Department of the New York City campus.

Bestqool Unveils the Key to Optimal Health: The Perfect Duration for Red Light Therapy Sessions

Retrieved on: 
Tuesday, March 26, 2024
Pigment, Health, Radiation, Burns, Fibromyalgia, Cell, Inflammation, Patient, Tissue, Muscle fatigue, Athlete, Arthritis, Light, Wound healing, Skin, Safety, Red light, Low-level laser therapy, Ageing, Medical imaging

Seattle, Washington, March 26, 2024 (GLOBE NEWSWIRE) -- In an exciting development for wellness enthusiasts and health-conscious individuals, Bestqool, has announced its insights into the optimal duration for Red Light Therapy sessions.

Key Points: 
  • Seattle, Washington, March 26, 2024 (GLOBE NEWSWIRE) -- In an exciting development for wellness enthusiasts and health-conscious individuals, Bestqool, has announced its insights into the optimal duration for Red Light Therapy sessions.
  • This revelation promises to enhance the efficacy and safety of Red Light Therapy, a popular and effective treatment that has captivated global attention for its numerous health benefits.
  • How Long Should Red Light Therapy Sessions Last?
  • In pain relief, Red Light therapy duration can last as long as 15 to 30 minutes instead.

Royale®, a Trusted Canadian Tissue Brand for Over 60 Years, Launches A New Premium Diaper

Retrieved on: 
Tuesday, March 26, 2024
Dry, Chlorine, Family, Parent, Skin

DIEPPE, New Brunswick, March 26, 2024 (GLOBE NEWSWIRE) -- Canadians have trusted Royale tissue products for over 60 years and now the brand welcomes a new member to its family, baby diapers.

Key Points: 
  • DIEPPE, New Brunswick, March 26, 2024 (GLOBE NEWSWIRE) -- Canadians have trusted Royale tissue products for over 60 years and now the brand welcomes a new member to its family, baby diapers.
  • “Our customers appreciate the quality and softness of Royale tissue products.
  • “We’re proud to be the only Canadian manufacturer of diapers and a trusted tissue brand,” said Robert Irving.
  • “We are confident Canadian parents will grow to appreciate this new high quality Royale diaper.”

Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Retrieved on: 
Tuesday, March 26, 2024
Development, Growth, Skin cancer, Immunotherapy, Genentech, Philip, Patient, Lung, RP1, Skin, Cancer, Melanoma, Retirement, Marketing, BLA

WOBURN, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced changes to its executive leadership team designed to support the Company’s preparations for the commercial launch of RP1, pending regulatory submission and approval in anti-PD1 failed melanoma.

Key Points: 
  • Sushil Patel, Ph.D., will succeed Philip Astley-Sparke as CEO effective April 1, 2024.
  • Mr. Astley-Sparke will transition from his current role as CEO to Executive Chairman of the Board of Directors.
  • Dr. Patel joined Replimune three years ago initially as Chief Commercial Officer and served most recently as Chief Strategy Officer.
  • Prior to joining Replimune, Dr. Patel served as franchise head for lung, skin and rare cancers at Genentech.

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

Retrieved on: 
Tuesday, March 26, 2024
The Orange Book, NCE, Orange Book, Dermatology, Skin, Patent, Therapy, FDA, Approved drug, Food, Pharmaceutical industry

WEST CHESTER, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company’s lead product, YCANTH™, has received New Chemical Entity (“NCE”) Status and a listing in the Orange Book from the U.S. Food and Drug Administration (“FDA”), providing a minimum five years of regulatory exclusivity.

Key Points: 
  • The Company’s U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, excluding any patent term adjustment or patent term extension
    WEST CHESTER, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company’s lead product, YCANTH™, has received New Chemical Entity (“NCE”) Status and a listing in the Orange Book from the U.S. Food and Drug Administration (“FDA”), providing a minimum five years of regulatory exclusivity.
  • “We could not be more pleased to announce YCANTH™ has been granted NCE Status by the FDA,” said Ted White, Verrica’s President and Chief Executive Officer.
  • “Today’s announcement represents the continued execution of our Company’s comprehensive intellectual property strategy to maximize the patent and regulatory protections surrounding YCANTH™ and further underscores the product’s innovation and intrinsic value in the dermatology market.
  • While NCE status will provide YCANTH™ with a minimum of five years of protection, we anticipate our full patent portfolio to provide protection from generic competition for the next decade and potentially beyond.”
    Formally described as the Approved Drug Products with Therapeutic Equivalence Evaluations, the Orange Book is an FDA publication that provides a list of drugs approved as safe and effective and also serves as the regulatory resource for information on drug marketing availability, bioequivalence, drug substitution, and patent and exclusivity data.1 The Orange Book also lists patents covering those drugs, approved methods of their use, and regulatory exclusivities to which they may be entitled.

Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”

Retrieved on: 
Tuesday, March 26, 2024
Connected, HIV-1, Amazon Prime Video, Breast milk, Face, Hypoesthesia, Patient, Chronic pain, Clostridioides, Heartburn, Lymph, Magnesium, Diarrhea, Myalgia, Spine, Allergy, Muscle weakness, Vonoprazan, Stomach, Vitamin, Dizziness, Potassium, Hip, Risk, Tongue, Chills, DTC, Safety, Food, PPI, Rash, Food and Drug Administration, GERD, Enzyme inhibitor, Skin, Esophagitis, HIV, Rilpivirine, Kidney, FDA, Esophagus, B-12, Weakness, Infection, Indigestion, Smart TV, Seizure, Inflammation, Polyp, Calcium, Extrapyramidal system, Bone fracture, Nausea, Spasm, Urine, Fever, Clostridioides difficile, Bleeding, Blood, Wrist, Blister, Vitamin B12, Human, Medicine, Pharmaceutical industry

FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announces the launch of its new broadcast ad and full-scale, Direct-to-Consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class treatment and encourage people to speak to their doctor about this new treatment option. VOQUEZNA (vonoprazan) is indicated for the healing and maintenance of healing of all severities of Erosive Esophagitis (EE), also referred to as Erosive GERD, and for the relief of related heartburn. VOQUEZNA represents the first major innovation to the U.S. Erosive GERD market in over 30 years.1

Key Points: 
  • The campaign will also be featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads.
  • “Phathom is excited to launch our first campaign directly to, and for, the people whose lives we strive to improve every day.
  • To view a video of the “VOQUEZNA Can Kick Some Acid” commercial, click here.
  • Talk with your healthcare provider about the possibility of fundic gland polyps if you have been on VOQUEZNA for a long time.

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Tuesday, March 26, 2024
Diagnosis, Blood pressure, Efgartigimod alfa, System, Urination, Urinary tract infection, MHLW, Chest pain, Rituximab, Allergy, Disease, Infection, Risk, Headache, Patient, Sore throat, IWG, History, ITP, Chills, Quality of life, Cough, Euronext, Rash, Respiratory tract infection, Splenectomy, Medicine, Skin, Fever, Antibody, Wheeze, Back pain, Shivering, Safety, Pain, Fatigue, Phlegm, Swelling, Food, Autoimmune disease, Nursing

“argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx is on a mission to deliver transformative medicines for people living with severe autoimmune disease,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • By reducing circulating autoantibodies, VYVGART is uniquely designed to serve as a precision intervention that targets the underlying disease biology of ITP.
  • ADVANCE successfully met its primary endpoint, demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • Do not use VYVGART if you have a serious allergy to efgartigimod alfa or any of the other ingredients in VYVGART.

Torani Launches Dragon Fruit Syrup: A Vibrant, Subtly Sweet & Easy-to-Mix Flavor

Retrieved on: 
Tuesday, April 9, 2024
Retail, Restaurant, Bar, Food, Beverage, Consumer, Energy, Target, Partnership, Coffee, Light, Tourism, Skin, Generation Z, Fruit, Traction, Multimedia, Soft drink

Torani , a leader in the flavor industry for 99 years, today announced the newest addition to its portfolio of more than 150 syrups and sauces: Torani Dragon Fruit Syrup .

Key Points: 
  • Torani , a leader in the flavor industry for 99 years, today announced the newest addition to its portfolio of more than 150 syrups and sauces: Torani Dragon Fruit Syrup .
  • View the full release here: https://www.businesswire.com/news/home/20240409166521/en/
    Torani today announced the newest addition to its portfolio of more than 150 syrups and sauces: Torani Dragon Fruit Syrup.
  • Dragon fruit, also known as pitaya, is a unique-looking fruit characterized by its textured bright pink or red outer skin.
  • Torani Dragon Fruit Syrup is well-suited to layer with a variety of mainstream flavors to create a new and interesting combination of tastes.

ästhetik skincare Launches Vegan, Cruelty-Free Tinted Sunscreen

Retrieved on: 
Tuesday, April 9, 2024
Fashion, Cosmetics, Online Retail, Retail, Consumer, Women, Sunburn, Hyaluronic acid, Woman, Carcinogen, SPF, Skin, Face, Science, American Academy, Skin cancer, Animal

ästhetik skincare , the Florida-based clean skincare brand founded by esthetician Alexis Pfropper, today launches its newest product – the organic tinted mineral sunscreen SPF 50 .

Key Points: 
  • ästhetik skincare , the Florida-based clean skincare brand founded by esthetician Alexis Pfropper, today launches its newest product – the organic tinted mineral sunscreen SPF 50 .
  • The organic tinted mineral sunscreen SPF 50 is packed with botanicals including jojoba oil, sea buckthorn oil, hyaluronic acid and more so your skin looks glowy and healthy every time you put it on.”
    The organic tinted mineral sunscreen SPF 50 is suitable for all skin types.
  • ästhetik skincare is a Florida-based brand created by 30 under 30 sensation Alexis Pfropper, a skilled esthetician and entrepreneur.
  • ästhetik skincare products are made with plant-based ingredients and never tested on animals.